WooGene B&G Co., Ltd (KOSDAQ:018620)

South Korea flag South Korea · Delayed Price · Currency is KRW
860.00
-2.00 (-0.23%)
At close: Dec 5, 2025
-4.55%
Market Cap 24.84B
Revenue (ttm) 54.77B
Net Income (ttm) -6.11B
Shares Out 28.89M
EPS (ttm) -214.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,451
Average Volume 35,987
Open 862.00
Previous Close 862.00
Day's Range 856.00 - 880.00
52-Week Range 815.00 - 1,027.00
Beta 0.36
RSI 43.73
Earnings Date Nov 13, 2025

About WooGene B&G

WooGene B&G Co., Ltd. engages veterinary medicines, microbial technology, and vaccines business in South Korea and internationally. It offers antibiotic, vaccine, nutrient, anti-inflammation, metabolic stimulant, and iron supplement products for swine, poultry, cattle, aquatic animals, companion animals, and raw materials, as well as operates vaccine research center. The company was formerly known as WooJin Co., Ltd. and changed its name to WooGene B&G Co., Ltd. in March 2001. WooGene B&G Co., Ltd. was founded in 1977 and is headquartered in Hw... [Read more]

Industry Pharmaceutical Preparations
Founded 1977
Employees 99
Stock Exchange KOSDAQ
Ticker Symbol 018620
Full Company Profile

Financial Performance

In 2024, WooGene B&G's revenue was 55.68 billion, a decrease of -3.87% compared to the previous year's 57.92 billion. Losses were -5.22 billion, 341.0% more than in 2023.

Financial Statements

News

There is no news available yet.